BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, which is growing market ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are ...

Elucid’s AI software helps physicians visualise arterial plaque build-up to assess patients’ risk of cardiovascular disease ...

Eli Lilly & Co.'s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, ...

Aldeyra Therapeutics has once again filed for Food and Drug Administration of its proposed reproxalap drug candidate for the treatment of signs and symptoms of dry-eye disease.

Summit's focus over the next three years or so will be to wrap up its two late-stage clinical programs for treating certain ...

A new vaccine was approved by the FDA in August, and it's available now, specifically for the new omicron variant, KP.2.

With only 12% 1 of therapies surviving the gauntlet of Phase III trials to receive FDA approval, and the cost to bring a drug ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

WELLlife, a leading innovator in medical diagnostic and testing solutions, is increasing accessibility to respiratory illness ...

Early results of a real-world study of faricimab demonstrated sustainable improvements in visual acuity and retinal anatomic ...

The FDA announced that nearly a dozen of 19 recalled guacamole products were given the agency's most dangerous warning label ...